Navigation Links
Alere Inc. Announces Offering of $450 Million of Senior Notes
Date:11/27/2012

WALTHAM, Mass., Nov. 27, 2012 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company") announced today that it intends to offer $450 million of senior notes due 2018 through a private placement, subject to market and other conditions.  The Company intends to use the net proceeds from the offering to finance its announced cash tender offer to repurchase any and all of its outstanding $250.0 million aggregate principal amount of 7.875% Senior Notes due 2016 (the "2016 Notes"), to repay outstanding revolving borrowings in the aggregate principal amount of approximately $97.5 million under its credit agreement and for working capital and other general corporate purposes, including the financing of potential acquisitions or investments, stock repurchases and capital expenditures.  The Company may also use a portion of the net proceeds to pay all or a portion of any post-closing payment, earn-out payment or other form of deferred or contingent consideration for previously completed acquisitions.

The private placement, which is expected to commence immediately, will be to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and outside the United States pursuant to Regulation S under the Securities Act.  The notes are not being registered under the Securities Act.  Unless so registered, the notes may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the expected offering and the use of proceeds. These statements reflect Alere's current views with respect to future events and are based on management's current assumptions and information currently available. Actual results may differ materially due to numerous factors including, without limitation, risks associated with market and economic conditions. Alere undertakes no obligation to update any forward-looking statements contained herein.


'/>"/>
SOURCE Alere Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
2. SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the board of directors violated fiduciary duties owed to Vertex shareholders.
3. Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
4. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
5. Golden Meditech Announces 2012 / 2013 Interim Results
6. TriReme Announces a New Round of Financing Totalling US$18 Million
7. Baby Quasar announces the launch of its next-gen skin care tool, Clear Rayz, for the treatment of acne
8. Accera Announces Initiation of Clinical Trial for AC-1204
9. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
10. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
11. Trovagene Announces Closing of Private Placement of $3.76 Million from the Sale of Restricted Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... YORK , Feb. 22, 2017 Summary ... cell lung cancer partnering deals and agreements entered into ... full report: http://www.reportlinker.com/p03605668-summary/view-report.html Description The Global ... 2010 report provides understanding and access to partnering deals ... companies. - Trends in partnering deals ...
(Date:2/22/2017)... Feb. 22, 2017  Corin Group announced today the ... used to treat patients with both a massive rotator ... The condition, known as cuff tear arthropathy, causes pain ... The Humelock Reversed Shoulder System, which was ... company based near Lyon, France , ...
(Date:2/22/2017)... 2017 Research and Markets has announced ... Review, 2016" report to their offering. ... Dermatological conditions are ... approximately one-third of the US population suffers from at least ... of the dermatology market has remained saturated with established and ...
Breaking Medicine Technology:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and athletics. It’s enough to overwork even the sharpest brain. , Power On, ... peak healthy activity without over clocking the brain. Each capsule contains Cognizin® Citicoline, ...
(Date:2/22/2017)... ... ... The National Academy of Certified Care Managers (NACCM) has ... period. NACCM, a nonprofit organization, has provided the premier certification for Care Managers ... to ensure that newly certified professionals are prepared to work effectively on behalf ...
(Date:2/22/2017)... ... February 22, 2017 , ... A ... smaller and sometimes harder to reach ones, according to the results of a ... Stroke Conference in Houston by Ricardo A. Hanel, MD, PhD, neurovascular surgeon with ...
(Date:2/22/2017)... ... 2017 , ... The first-ever National Heart Valve Disease Awareness ... join together to increase recognition about the risks of heart valve disease (HVD) ... mark a nationwide movement to raise awareness about a disease that has not ...
(Date:2/22/2017)... Pittsburgh, PA (PRWEB) , ... February 22, 2017 , ... ... why some people seem to derive a heart-protective benefit from eating soy foods, while ... , Japanese men who are able to produce equol—a substance made by some ...
Breaking Medicine News(10 mins):